ArticleDiabetology & metabolic syndrome2023
Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990-2019: analysis of data from the 2019 Global Burden of Disease Study.
Article in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- The changing etiology of liver cancer: A comparative study of global and Chinese burden trends from hepatitis dominance to metabolic risks (1990-2021) and forecasts to 2035.Liver research (Beijing, China) · 2026Article
- Fasting blood glucose to high-density lipoprotein cholesterol ratio and MASLD risk: non-linear association and BMI mediation in non-diabetic adults.Frontiers in nutrition · 2026Article
- Article
- Incidence and mortality trend of liver cancer in Iran from 1990 to 2021: an epidemiological investigation using the Global Burden of Disease study.Annals of medicine and surgery (2012) · 2025Article
- A systematic analysis and prediction of the disease burden of ischemic heart disease caused by hyperglycemia.Journal of diabetes investigation · 2025Article
- Impact of high fasting plasma glucose on liver cancer burden in China: a comprehensive analysis of trends from 1990 to 2021.Frontiers in nutrition · 2025Article
- A comparison of trends in the incidence of non-alcoholic steatohepatitis-related liver cancer in the BRICS countries from 1990 to 2021, alongside projections for the next 15 years.Frontiers in oncology · 2025Article
- Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels.Frontiers in nutrition · 2025Article
- Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990-2021) and future projections to 2045.Frontiers in public health · 2025Article
- Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin.Molecular biology reports · 2024Article
- The burden of liver cancer in Mongolia from 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Frontiers in oncology · 2024Article
- Time trends in Alzheimer's disease mortality attributable to metabolic risks and smoking in China from 1990 to 2019: an age-period-cohort analysis.Frontiers in aging neuroscience · 2024Article
- Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.Journal of gastroenterology · 2023Article
- Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.World journal of gastroenterology · 2023Review
- Temporal trends in mortality of tuberculosis attributable to high fasting plasma glucose in China from 1990 to 2019: a joinpoint regression and age-period-cohort analysis.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundExperimental and epidemiological studies have indicated an association between diabetes exposure and an increased risk of liver cancer due to nonalcoholic steatohepatitis (NASH). However, to date, no systematic study has specifically investigated the burden of NASH-related liver cancer due to exposure to high fasting plasma glucose (HFPG) levels worldwide.
methodsThe number and rate of deaths and disability-adjusted life years (DALYs) from HFPG-induced NASH-related liver cancer were estimated based on the results of the 2019 Global Burden of Disease Study. The estimated annual percentage changes (EAPCs) for age-standardized death or DALYs rates were calculated using a generalized linear model with a Gaussian distribution to quantify the temporal trends in the global burden of NASH-related liver cancer attributable to HFPG. The strength and direction of the association between the sociodemographic index (SDI) and death or DALY rate were measured using Spearman's rank-order correlation.
resultsGlobally, approximately 7.59% of all DALY and 8.76% of all mortalities of NASH-related liver cancer in 2019 were due to HFPG. The age-standardized death and DALY rates of NASH-related liver cancer attributable to HFPG increased from 1990 to 2019. The corresponding EAPCs were 0.69 (95% UI 0.48-0.89), and 0.30 (95% UI 0.05-0.56), respectively. This increasing pattern was most obvious in the high- and low-SDI regions. The age-standardized mortality and DALYs rate of NASH-related liver cancer attributable to HFPG varies considerably worldwide, with the middle SDI region having the highest death and DALY rates in 2019 (DALY 0.96 [95% UI 0.23-2.18]; death 0.05 [95% UI 0.01-0.11]).
conclusionThe burden of NASH-related liver cancer attributable to HFPG has increased over the past three decades, particularly in regions with high and low SDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.